CTI Life Sciences Fund L.P.
CTI Life Sciences Fund L.P., established in 2006, is a Montreal-based venture capital firm that invests in emerging life sciences companies in North America, with a focus on the United States and Canada, particularly Quebec. The firm targets pre-clinical to proof-of-concept and proof-of-concept to Phase III stages in pharmaceutical development, with a preference for biotechnology, biopharmaceuticals, drugs, and medical devices. CTI Life Sciences typically invests $5 million to $50 million in the first round, aiming for a two to five times bump-up upon exit, which it primarily achieves through mergers and acquisitions. The firm manages over $345 million in assets across multiple funds.
Top Stages
Past deals in Montreal
Epitopea
Seed Round in 2024
Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.
Epitopea
Seed Round in 2022
Epitopea is a transatlantic biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a novel class of tumor-specific antigens. The company utilizes a proprietary technique that integrates immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's genetic material. This approach, developed through research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal, aims to create therapies that selectively eliminate malignant cells while preserving healthy tissue. By targeting antigens that are broadly shared among patients with the same cancer type, Epitopea seeks to enhance treatment efficacy while minimizing side effects and providing durable benefits.
PreciThera
Series A in 2017
PreciThera, Inc. is a biotechnology company based in Montreal, Canada, founded in 2016. It specializes in developing biological therapeutics for rare bone diseases, particularly targeting heterogeneous genetic disorders that manifest as bone dysfunction. By leveraging computational technology and a comprehensive understanding of disease pathology, PreciThera aims to create precision medicines that address both skeletal and extraskeletal symptoms associated with these conditions. Its targeted therapeutic strategies seek to enhance treatment options for patients, focusing on traditional protein replacement therapies to improve overall health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.